Podcast

Precision Insights Podcast

Conversations with innovators moving from personalized to precision healthcare


Tom Parry President of the Integrated Benefits Institute (IBI), joined us for a conversation on the value of good health.

It was Tom’s vision and leadership that resulted in the creation of IBI in 1995. Tom has guided IBI to become the leading research organization focused on health and productivity and has led the growth of the organization to nearly 1,200 corporate members, representing more than 20 million U.S. workers.


Carrie Hurwitz Williams, Principal at McKesson Ventures, joined us for a conversation on emerging trends in precision medicine, pockets of adoption and organizations addressing business challenges facing the health care industry.

Carrie has nearly 15 years of healthcare experience from several vantage points within the healthcare industry. Prior to joining McKesson Ventures, she served as Vice President, Strategy and Business Development for San Francisco-based digital therapeutics pioneer Omada Health.


Bob Mehr is a business innovator and industry leader who began his career as a Compounding Pharmacist. Bob Mehr has been the President and CEO of Pure Integrative Pharmacy since 1999 opening 14 stores. His experience with precision prescribing goes beyond his practice and has had a tremendous impact on his own health.

‘A patient died right in front of me because they had the wrong medication. We need to stop practicing medicine like this, we need to be more precise. I opened my pharmacies because I wanted a change, and I wanted everyone to take advantage of it’ Bob Mehr, President and CEO of Pure Integrative Pharmacy

Dr. Liam Brunham, Assistant Professor in the Department of Medicine at the University of British Columbia and a Principal Investigator at the UBC Centre for Heart and Lung Innovation join us for a conversation on adverse drug reactions, pharmacogenetics and iPSC.

Imagine being able to reprogram your cells to find the right medication for your heart. Understanding the biological and molecular processes underlying adverse drug reactions (ADRs) is fundamental to develop innovative approaches to prevent them. One of the most promising technologies to identify the genetic mechanisms behind ADRs are induced pluripotent stem cells (iPSCs).